$IPX

IPERIONX Ltd

No enriched coverage for $IPX in the last 7 days.

No SEC Form 4 filings for $IPX in the last 30 days.

Med

Securities Fraud Investigation Into IperionX Limited (IPX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into IperionX Limited (IPX) following a disclosure by the company regarding a "typographic error" in its financial report. This error, concerning a right-of-use assets value, led to a significant drop in IperionX's stock price. The firm is urging investors who lost money to contact them to explore potential claims under federal securities laws.

A Look At IperionX (ASX:IPX) Valuation After New U.S. Army Prototype Titanium Order

IperionX (ASX:IPX) recently secured a US$0.3 million prototype order for lightweight titanium components for U.S. Army ground combat systems, following significant share price growth over the past year. While its Price-to-Book ratio of 17.4x suggests overvaluation compared to peers, a Discounted Cash Flow (DCF) model indicates the shares might be trading at a substantial discount to their estimated fair value. The company, however, remains unprofitable with no reported revenue, presenting risks despite its future potential.

IperionX Shares Surge on US Army Deal

IperionX shares surged over 7% on Friday, extending a five-day rally, after the company received an order to manufacture lightweight titanium components for the US Army. This contract, involving American Rheinmetall, is for heavy ground combat vehicles and is seen by analysts as a potential precursor to more substantial future awards. The company, which focuses on low-carbon titanium production and developing a fully integrated supply chain, also holds strategic value in its US-based Titan mine, which is believed to be undervalued.